Mydrane (Lidocaine Hydrochloride Monohydrate, Phenylephrine Hydrochloride, Tropicamide)

Lidocaine blocks voltage‑gated sodium channels, producing local anesthesia of ocular tissues. Phenylephrine activates alpha‑1 adrenergic receptors on the iris dilator muscle, causing contraction and pupil dilation. Tropicamide antagonizes muscarinic receptors in the iris sphincter, leading to relaxation, cycloplegia, and further dilation. Together they create fast, sustained mydriasis and analgesia.

The dose of Mydrane is determined by the operating ophthalmologist based on the specific surgical protocol and patient characteristics. The prescribing clinician selects the appropriate volume for intracameral injection; no fixed regimen is provided in public information.

Safety data for Mydrane in pregnancy and lactation are limited. It should be used only if the potential therapeutic benefit justifies any potential risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with the patient and consider alternative options when appropriate.

To order Mydrane, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

Mydrane combines three agents in a single intracameral formulation, offering simultaneous anesthesia and mydriasis. Compared with using separate lidocaine and phenylephrine/tropicamide drops, Mydrane provides faster onset, more consistent pupil dilation, and reduces the number of applications. Alternative combination products exist, but Mydrane’s single‑step injection can simplify workflow and improve surgical efficiency.

Mydrane should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the solution from direct light and moisture. Do not freeze or shake the vial. Inspect the product before use for any particulate matter or discoloration.

Mydrane is administered by a sterile intracameral injection directly into the anterior chamber of the eye at the start of surgery. The injection is performed by a qualified ophthalmic surgeon using aseptic technique, delivering the prescribed volume to achieve rapid mydriasis and anesthesia.

The most serious risks include severe allergic reactions such as anaphylaxis, sustained elevation of intra‑ocular pressure that may require intervention, persistent mydriasis causing photophobia, corneal edema, and systemic cardiovascular effects like hypertension or arrhythmia. Prompt recognition and management of these events are essential.

Mydrane should be avoided in patients with known hypersensitivity to lidocaine, phenylephrine, or tropicamide. It is also contraindicated in individuals with uncontrolled hypertension, severe cardiovascular disease, or those in whom significant intra‑ocular pressure elevation would be hazardous, such as certain glaucoma patients. Clinical judgment is required for each case.